Autolus Therapeutics (AUTL) Projected to Post Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is expected to release its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Autolus Therapeutics to post earnings of ($0.27) per share and revenue of $23.9160 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 3:00 AM ET.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $1.56 on Thursday. The stock has a market cap of $415.18 million, a PE ratio of -1.88 and a beta of 1.95. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $2.70. The firm has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.53.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Zacks Research downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Needham & Company LLC cut their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, HC Wainwright assumed coverage on shares of Autolus Therapeutics in a research report on Tuesday, February 17th. They set a “buy” rating and a $9.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.50.

Institutional Trading of Autolus Therapeutics

Large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company increased its stake in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after buying an additional 11,289 shares during the period. Invesco Ltd. boosted its position in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter worth about $28,000. SmartHarvest Portfolios LLC bought a new position in Autolus Therapeutics in the 4th quarter worth about $43,000. Finally, Two Sigma Investments LP increased its position in shares of Autolus Therapeutics by 17.3% during the third quarter. Two Sigma Investments LP now owns 172,143 shares of the company’s stock worth $281,000 after acquiring an additional 25,346 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.